Montelukast for Asthma
Montelukast is an appropriate alternative therapy for mild persistent asthma in patients unable or unwilling to use inhaled corticosteroids, but inhaled corticosteroids remain the preferred first-line treatment due to superior efficacy in controlling symptoms and preventing exacerbations. 1
Positioning in Asthma Treatment
Mild Persistent Asthma (Step 2)
- Preferred treatment: Low-dose inhaled corticosteroid (ICS)
- Alternative treatment: Montelukast is listed as an acceptable alternative alongside cromolyn, nedocromil, or theophylline 1
- Key advantage: Once-daily oral administration provides ease of use and high compliance rates 1
- Important caveat: While montelukast improves asthma control compared to placebo, inhaled corticosteroids are superior for controlling daytime and nighttime symptoms 2
Moderate Persistent Asthma (Step 3-4)
- Preferred approach: Low-to-medium dose ICS plus long-acting beta-agonist (LABA)
- Alternative approach: Low-to-medium dose ICS plus montelukast 1, 3
- Evidence limitation: Studies of ICS plus montelukast combination are limited, particularly in children under 12 years 3
- Critical finding: Adding montelukast as a third medication to medium-to-high dose ICS plus LABA in severe persistent asthma showed no additional benefit 3
Dosing by Age
FDA-approved dosing 4:
- Ages 1-5 years: 4 mg chewable tablet once daily
- Ages 6-14 years: 5 mg chewable tablet once daily
- Ages 15 years and older: 10 mg tablet once daily
Timing: Administer in the evening for asthma (morning or evening acceptable for allergic rhinitis) 4
Administration: Can be taken without regard to food 4
Clinical Efficacy Data
Pediatric Evidence
The PACT trial 2 provides the most definitive pediatric data:
- 285 children (ages 6-14) with mild-to-moderate persistent asthma
- Fluticasone monotherapy gained 42 more asthma control days per year compared to montelukast (p=0.004)
- Number needed to treat: approximately 7 children need fluticasone instead of montelukast to achieve one additional treatment response
- Growth rates were similar across all groups (no significant difference)
Adult Evidence
In adults with mild-to-moderate persistent asthma 4:
- Montelukast reduced "as-needed" beta-agonist use by 26.1% versus 4.6% for placebo
- Reduced nocturnal awakenings by 34% versus 15% for placebo
- Improved FEV1 by mean 7.49% versus placebo
Comparative Effectiveness
- Meta-analysis shows ICS superior for controlling symptoms, especially nighttime symptoms
- Montelukast inferior to ICS (OR 1.63) and ICS plus LABA (OR 3.94) for preventing exacerbations 6
Special Populations and Indications
Young Children (2-5 years)
- Limited efficacy data in this age group 1, 3
- FDA approval based primarily on safety data and pharmacokinetic extrapolation 3
- May reduce exacerbations in intermittent asthma associated with viral infections 7
Add-on Therapy
- When low-dose ICS insufficient: LABA is preferred add-on therapy over montelukast 8
- Montelukast may benefit the small subset who respond better to it than LABA 8
Concomitant Allergic Rhinitis
- Montelukast approved for both asthma and allergic rhinitis 9
- Particularly attractive option when treating combined upper and lower airway disease 9
- May be preferred in families with "steroid-phobia" 9
Critical Safety Warning
The FDA issued a Boxed Warning for montelukast in March 2020 10 regarding neuropsychiatric events including:
- Agitation
- Depression
- Sleep disturbances
- Suicidal thoughts and behavior
Clinical implication: Reserve montelukast for patients where alternative treatments are inadequate or not tolerated. Counsel patients and families about these risks.
Monitoring
No routine laboratory monitoring required 4
Clinical monitoring should assess:
- Symptom control (daytime and nighttime)
- Rescue inhaler use (>2 days/week indicates inadequate control)
- Asthma exacerbations
- Neuropsychiatric symptoms (given FDA warning)
Response assessment: Conduct an N-of-1 trial approach 8:
- Trial montelukast for 4-6 weeks
- Objectively assess response using symptom scores, peak flow, and rescue medication use
- Discontinue if no convincing response - do not leave patients on ineffective therapy 8
Common Pitfalls
Overprescribing: Clinically, more children receive montelukast than evidence suggests will respond 8. Always attempt ICS first unless contraindicated.
Continuing without response: No biomarker predicts montelukast response 8. Must perform clinical trial and discontinue if ineffective.
Using as monotherapy in moderate-severe asthma: Montelukast alone is insufficient for moderate-to-severe disease 1, 6.
Adding as third-line agent: No benefit when added to ICS plus LABA 3.
Ignoring neuropsychiatric risks: The 2020 FDA Boxed Warning necessitates careful patient selection and monitoring 10.